Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Phase 2
Not yet recruiting
- Conditions
- Malignant Melanoma with MetastasisMalignant MelanomaMalignant Melanoma Stage IIIcMalignant Melanoma Stage IV
- Interventions
- Biological: RAPA-201 Rapamycin Resistant T CellsDrug: Chemotherapy Prior to RAPA-201 Therapy
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 65
- Registration Number
- NCT06708455
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Intermountain Medical Center, Murray, Utah, United States
RAPA-501 Therapy for ALS Expanded Access Protocol
Phase 2
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Biological: RAPA-501 Autologous T cells
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06169176
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Hospital Phoenix, Scottsdale, Arizona, United States
RAPA-201 Therapy of Solid Tumors
Phase 1
Recruiting
- Conditions
- Esophageal AdenocarcinomaGastric Junction AdenocarcinomaSquamous Cell Carcinoma of Oral CavitySmall Cell and Non-small Cell Lung CancerHead and Neck CancerSquamous Cell Carcinoma of Other Specified Sites of SkinSolid TumorTriple Negative Breast CancerGastric CancerSquamous Cell Carcinoma of Larynx
- Interventions
- Biological: RAPA-201 Rapamycin Resistant T CellsDrug: Chemotherapy Prior to RAPA-201 Therapy
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 22
- Registration Number
- NCT05144698
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
RAPA-501-Allo Therapy of COVID-19-ARDS
Phase 1
Terminated
- Conditions
- Severe COVID-19 Disease
- Interventions
- Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19Other: Placebo
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 1
- Registration Number
- NCT04482699
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
RAPA-501 Therapy for ALS
Phase 2
Recruiting
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Biological: RAPA-501 Autologous T cells
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 41
- Registration Number
- NCT04220190
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Phase 2
- Conditions
- Relapsed, Refractory Multiple Myeloma
- Interventions
- Biological: RAPA-201 Autologous T cells
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 27
- Registration Number
- NCT04176380
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath